Health Condition 1: Z111- Encounter for screening for respiratory tuberculosis
Conditions
Interventions
None listed
Sponsors
Institute of Teaching and Research in Ayurveda Jamnagar
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients willing to comply with all study procedures and availability for the duration of the study. 2.Patients having Rifampsin resistance or Isoniazid resistance. 3.Patients with primary and acquired resistance to MTB.
Exclusion criteria
Exclusion criteria: 1.Patients having uncontrolled cardiac, renal, hepatic disease, HIV-AIDS, malignancy, cancer and other associated lung disease. 2.Pregnant and lactating women. 3.Patients who are getting first line (primary DS PTB) Anti tubercular treatment. 4.MDR PTB patients whose acute illness required intensive care. 5.Patient who are intolerated to ATD regimen 6.Extra pulmonary PTB patients will be excluded 7.Patients having both Rifampsin and Isoniazid or any other drug resistance from the ATD regimen. 8.Patients with longer (18-24 months) ATD regimen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that the trial drug will improve the outcome in the patients of MDR PTB (Rajyakshma) in terms of early reduction of symptoms & toxic effects of ATT like cough, fever, hemoptysis, dyspnoea, chest pain etc. & atleast one grade decline in AFB smear.Timepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The trial drug will have a positive effect on health related quality of life in the patients of MDR PTB (Rajyakshma) in terms of physical, psychological, social & environmental parameter and nutritional status of the patient.Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactDr Mandip Goyal
Institute of Teaching and Research in Ayurveda Jamnagar.
Outcome results
None listed